Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes
- PMID: 20224962
- DOI: 10.1007/s15010-010-0008-1
Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes
Abstract
Background: There has been an increasing incidence of carbapenem-resistant Acinetobacter baumannii (CRAB) infections in recent years. The objective of this study was to determine specific risk factors for and outcome of bacteremia due to CRAB isolates among our ICU patients with A. baumannii bacteremia.
Patients and methods: Among 96 patients with ICU-acquired A. baumannii bacteremia, 30 patients with CRAB were compared with the remaining 66 with carbapenem-susceptible A. baumannii (CSAB) isolates.
Results: Recent ventilator-associated pneumonia (VAP) due to CRAB (OR 16.74, 95% CI 3.16-88.79, p = 0.001) and a greater number of intravascular devices (OR 3.93, 95% CI 1.9-13.0, p = 0.025) were independently associated with CRAB bacteremia acquisition. Patients with CRAB bacteremia had a lower severity of illness on admission than those with CSAB. Although, by univariate analysis, patients with CRAB were more likely to have had exposure to colistin, carbapenems and linezolid, multivariate analysis did not revealed any significant association. The mortality was not different between patients with CRAB and CSAB bacteremia (43.3 vs. 46.9%, p = 0.740). Severity of organ failure (OR 1.42, 95% CI 1.20-1.67, p = 0.001), and increased white blood cell (WBC) count (OR 1.09, 95% CI 1.01-1.19, p = 0.036), at bacteremia onset were independently associated with mortality.
Conclusion: VAP due to CRAB and excess use of intravascular devices are the most important risk factors for CRAB bacteremia in our ICU. Severity of organ failure and WBC count at A. baumannii bacteremia onset are independently associated with mortality.
Similar articles
-
Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Acinetobacter baumannii complex bacteraemia: experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network.J Med Microbiol. 2020 Jul;69(7):949-959. doi: 10.1099/jmm.0.001222. J Med Microbiol. 2020. PMID: 32584215
-
Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study.J Infect Chemother. 2016 Jul;22(7):444-9. doi: 10.1016/j.jiac.2016.03.013. Epub 2016 May 24. J Infect Chemother. 2016. PMID: 27229539
-
Insights into the epidemiology, risk factors, and clinical outcomes of carbapenem-resistant Acinetobacter baumannii infections in critically ill children.Front Public Health. 2023 Nov 30;11:1282413. doi: 10.3389/fpubh.2023.1282413. eCollection 2023. Front Public Health. 2023. PMID: 38098829 Free PMC article.
-
Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.Am J Infect Control. 2019 Sep;47(9):1140-1145. doi: 10.1016/j.ajic.2019.03.003. Epub 2019 Apr 17. Am J Infect Control. 2019. PMID: 31003750
-
The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis.Emerg Microbes Infect. 2019;8(1):1747-1759. doi: 10.1080/22221751.2019.1698273. Emerg Microbes Infect. 2019. PMID: 31805829 Free PMC article.
Cited by
-
Nosocomial, Healthcare-Associated, and Community-Acquired Acinetobacter baumannii in China: Clinical Characteristics, Antimicrobial Resistance Patterns and Risk Factors Associated with Carbapenem Resistance.Infect Drug Resist. 2024 Sep 19;17:4089-4099. doi: 10.2147/IDR.S469244. eCollection 2024. Infect Drug Resist. 2024. PMID: 39319039 Free PMC article.
-
Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis.JAC Antimicrob Resist. 2021 Nov 5;3(4):dlab157. doi: 10.1093/jacamr/dlab157. eCollection 2021 Dec. JAC Antimicrob Resist. 2021. PMID: 34755112 Free PMC article. Review.
-
Antimicrobial peptide 2K4L disrupts the membrane of multidrug-resistant Acinetobacter baumannii and protects mice against sepsis.Front Microbiol. 2023 Oct 24;14:1258469. doi: 10.3389/fmicb.2023.1258469. eCollection 2023. Front Microbiol. 2023. PMID: 37942076 Free PMC article.
-
Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections.Antimicrob Agents Chemother. 2011 Oct;55(10):4844-9. doi: 10.1128/AAC.01728-10. Epub 2011 Aug 8. Antimicrob Agents Chemother. 2011. PMID: 21825287 Free PMC article.
-
Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia.Infect Chemother. 2013 Sep;45(3):325-30. doi: 10.3947/ic.2013.45.3.325. Epub 2013 Sep 27. Infect Chemother. 2013. PMID: 24396634 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources